Analysts expect Merus NV (NASDAQ:MRUS) to report sales of $7.82 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Merus’ earnings. The highest sales estimate is $8.66 million and the lowest is $6.78 million. Merus posted sales of $7.57 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.3%. The business is scheduled to report its next quarterly earnings results on Thursday, December 26th.
On average, analysts expect that Merus will report full year sales of $31.88 million for the current year, with estimates ranging from $30.89 million to $32.86 million. For the next fiscal year, analysts anticipate that the business will report sales of $49.17 million, with estimates ranging from $32.03 million to $81.28 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Merus.
Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Monday, August 19th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.03). Merus had a negative net margin of 104.10% and a negative return on equity of 41.68%. The firm had revenue of $6.27 million for the quarter, compared to analysts’ expectations of $8.62 million.
MRUS has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Merus from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, October 2nd. Roth Capital started coverage on shares of Merus in a research report on Friday, June 28th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, BidaskClub upgraded shares of Merus from a “hold” rating to a “buy” rating in a research report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Merus presently has an average rating of “Buy” and an average price target of $23.43.
Several large investors have recently modified their holdings of MRUS. JPMorgan Chase & Co. grew its stake in shares of Merus by 63.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock worth $123,000 after buying an additional 3,389 shares in the last quarter. Artal Group S.A. grew its stake in shares of Merus by 16.7% in the 2nd quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock worth $5,128,000 after buying an additional 50,000 shares in the last quarter. Athanor Capital LP purchased a new position in shares of Merus in the 2nd quarter worth $334,000. Finally, Morgan Stanley grew its stake in shares of Merus by 3.1% in the 2nd quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock worth $1,359,000 after buying an additional 2,788 shares in the last quarter. 52.00% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:MRUS traded up $0.29 during trading on Friday, reaching $16.70. 245 shares of the stock traded hands, compared to its average volume of 48,522. The stock has a 50-day moving average of $17.18 and a two-hundred day moving average of $15.40. Merus has a 52-week low of $11.00 and a 52-week high of $20.95. The stock has a market cap of $376.29 million, a P/E ratio of -9.01 and a beta of 0.24.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Featured Article: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.